CCR4 Modulators Block Treg Recruitment in EBV Cancers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges in effectively targeting regulatory T cells (Treg) to enhance antitumor immune responses, as existing methods often impact other immune cell populations and can trigger side effects, and there is a need for a more specific approach to block Treg recruitment to the tumor microenvironment.
Innovation Solution
The use of CCR4 modulators, such as specific compounds or antibodies, to selectively block the recruitment of Treg cells to the tumor microenvironment, potentially combined with anti-cancer agents like romidepsin, carboplatin, or Abraxane, to treat EBV-associated cancers by modulating the immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments are used to enhance antitumor immune responses, then immune activation is improved, but side effects increase due to impact on other immune cell populations
Solution Approach 1:
The invention targets a specific subset of immune cells (regulatory T cells expressing CCR4) rather than broadly activating all immune cells. By segmenting the immune response to specifically modulate Treg recruitment through CCR4 antagonism, the treatment enhances antitumor immunity while minimizing off-target effects on other immune cell populations.
Solution Approach 2:
The invention applies local quality by specifically blocking CCR4-mediated recruitment of Treg cells to the tumor microenvironment, rather than systemically suppressing all Treg cells or activating all immune cells. This localized modulation at the tumor site enhances antitumor response while preserving immune function in healthy tissues.
2Reliability
If Treg cells are depleted using antibodies or cytotoxic agents, then suppressive effects are reduced, but other immune cell populations are impacted
Solution Approach 1:
Instead of depleting all Treg cells systemically, the invention segments the approach by specifically blocking CCR4-mediated recruitment to the tumor microenvironment. This allows selective reduction of Treg suppressive effects at the tumor site while preserving Treg function in peripheral tissues and other immune cell populations.
Solution Approach 2:
The invention uses CCR4 antagonists as intermediaries to block the interaction between Treg cells and the tumor microenvironment. Rather than directly depleting Treg cells with antibodies or cytotoxic agents, the CCR4 antagonist mediates the effect by preventing chemokine-guided recruitment, thereby reducing suppressive effects without directly impacting Treg cell viability or other immune populations.
3Reliability
If CCR4 antagonism is used to block Treg recruitment, then Treg accumulation in TME is reduced, but treatment complexity increases
Solution Approach 1:
The invention leverages the existing CCR4-chemokine interaction pathway that naturally regulates Treg recruitment. By using small molecule CCR4 antagonists or monoclonal antibodies that block this established pathway, the treatment achieves Treg recruitment blocking through a single mechanism that can be combined with standard-of-care therapies, rather than requiring multiple complex interventions.
Data Source
AI summary
Disclosed herein are therapeutic methods of administering compounds that modulate the C—C chemokine receptor type 4 (CCR4) for the treatment of Epstein Bar virus (EBV) positive cancers and malignancies.